Handelsavisen
prelaunch
Companies Healthcare ZEOX.PK
ZE
ZEOX.PK OTC Diversified Pharmaceuticals

Zeox.Pk

$1,34
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-103,6 %
ROE
388,0 %
Net margin
-106,2 %
Debt / equity
-0,25
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-08-28
Ex-dividend
TR 1Y
About

ZEOX.PK operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.

Business. ZEOX.PK operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.

Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-08-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
388,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ZEOX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ZEOX.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-08-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ZEOX.PK operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Pharmaceuticals
    AI synthesis
    GENERATED

    ZEOX.PK exhibits a highly leveraged capital structure, with total liabilities of $2.95 billion and total equity of -$1.42 billion, resulting in a negative debt-to-equity ratio of -0.25. The company's liquidity position is weak, as evidenced by a current ratio of 0.33, indicating that current assets are insufficient to cover current liabilities. Operating cash flow is negative at -$718 million, and free cash flow is -$5.47 billion, signaling significant cash outflows and limited ability to fund operations or debt obligations.

    Profitability metrics are mixed. Gross profit of $4.27 billion suggests strong cost control in production, but this is offset by an operating loss of -$5.39 billion and a net loss of -$5.52 billion. Return on equity is positive at 3.88, but return on assets is negative at -3.62, indicating that the company is not generating returns sufficient to cover the cost of its assets. These figures fall below the industry median for profitability and return metrics, suggesting underperformance relative to peers.

    ZEOX.PK's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another. The absence of segment or geographic breakdown in the financial data further complicates the assessment of risk and growth potential.

    The company's growth trajectory is uncertain. With a net loss of -$5.52 billion and negative free cash flow of -$5.47 billion, ZEOX.PK is not currently generating the cash flow necessary to sustain operations or fund expansion. There is no disclosed revenue growth in the most recent period, and no forward-looking guidance is available to assess future performance. The lack of capital expenditure ($23 million) suggests limited investment in growth initiatives.

    Risk factors include a weak liquidity position, with negative net cash after subtracting total debt, and a high probability of continued operating losses. The company's dilution risk is currently low, as shares outstanding have not changed between basic and diluted counts. However, the negative equity position and high debt levels could necessitate future equity or debt financing, which may lead to dilution or increased financial risk.

    Recent events include the filing of financial statements that highlight the company's significant operating losses and negative cash flows. No recent earnings call transcripts or press releases have been disclosed that provide additional insight into the company's strategic direction or operational performance.

    Key takeaways
    • ZEOX.PK is operating at a significant net loss and has negative free cash flow, indicating a lack of financial sustainability.
    • The company's return on assets is negative, suggesting poor asset utilization and underperformance relative to industry standards.
    • ZEOX.PK's capital structure is highly leveraged, with total liabilities exceeding total assets and a negative equity position.
    • The company lacks geographic and segment diversification, increasing its exposure to market-specific risks.
    • Liquidity is a critical concern, with a current ratio of 0.33 and negative operating cash flow.
    • No recent strategic or operational developments have been disclosed that suggest a path to profitability or growth.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,34
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$1.4M
    Net cash
    -$353.0k
    Current ratio
    0.3
    Debt / equity
    -0.2
    ROA
    -3.6%
    ROE
    3.9%
    Cash conversion
    13.0%
    CapEx / revenue
    -0.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Aesthetic Dermatology Products
    low · business_description · 2026-07-04
    Autologous Cell Therapies
    low · business_description · 2026-07-04
    Stem Cell Therapies
    low · business_description · 2026-07-04
    Tissue Regeneration Biologics
    low · business_description · 2026-07-04

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Pharmaceuticals1 042,4B node revenueMCK 38,7%COR 30,8%CAH 21,4%DB 3,4%REGN 1,4%BIIB 0,9%ZTS 0,9%GRFS 0,8%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered setZEOX 0,0% · rank #34 of 40

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs ZEOX · multiples and returns
    MC
    MCK
    Mckesson Corp
    $827,14
    102,6B USD
    P/E
    21,2x
    vs self
    Div yield
    0,4 %
    vs self
    ROE
    -219,2 %
    vs self
    CO
    COR
    Cencora Inc
    $308,37
    60,2B USD
    P/E
    36,4x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    45,7 %
    vs self
    CA
    CAH
    Cardinal Health Inc
    $235,60
    57,0B USD
    P/E
    36,7x
    vs self
    Div yield
    0,9 %
    vs self
    ROE
    -55,9 %
    vs self
    DB
    DB
    DB.V
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    RE
    REGN
    REGENERON PHARMACEUTICALS, INC.
    $757,99
    81,0B USD
    P/E
    15,5x
    vs self
    Div yield
    vs self
    ROE
    14,2 %
    vs self
    BI
    BIIB
    BIOGEN INC.
    $201,74
    29,6B USD
    P/E
    21,3x
    vs self
    Div yield
    vs self
    ROE
    7,5 %
    vs self
    ZT
    ZTS
    Zoetis Inc
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GR
    GRFS
    Grifols SA
    $7,86
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-103,6 %Below median
    Net Margin-106,2 %Below median
    ROE388,0 %Best in class
    Capex / Rev-0,4 %Above median
    D/E-0,25Above P75
    Cash Conv0,13Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ZEOX.PK Market data — financials · 2026-05-30

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    4.5Kshares short+756.8% vs prior
    1days to cover
    352fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ZEOX.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2026-01-31 vs 2025-01-31): -12.0%Derived (calculated)
    • Debt-to-equity (FY 2026-01-31): -7.71xDerived (calculated)
    • Current ratio (FY 2026-01-31): 0.70xDerived (calculated)
    • Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 78.8%Derived (calculated)
    • Total assets (YoY) (2026-01-31 vs 2025-01-31): 65.9%Derived (calculated)
    • Current assets (annual): USD 2.01MSEC XBRL filing
    • Total liabilities (annual): USD 2.95MSEC XBRL filing
    • Shares outstanding (annual): 7.61MSEC XBRL filing
    • Total assets (annual): USD 2.57MSEC XBRL filing
    • Current liabilities (annual): USD 2.89MSEC XBRL filing
    • Shareholders' equity (annual): USD -383KSEC XBRL filing
    • Cost of revenue (YoY) (2025-10-31 vs 2024-10-31): 10.3%Derived (calculated)
    • Net income (YoY) (2025-10-31 vs 2024-10-31): -17.3%Derived (calculated)
    • Gross margin (FY 2025-10-31): 82.1%Derived (calculated)
    • Gross profit (YoY) (2025-10-31 vs 2024-10-31): 13.0%Derived (calculated)
    • Capex (YoY) (2025-10-31 vs 2023-10-31): -11.5%Derived (calculated)
    • R&D expense (YoY) (2025-10-31 vs 2024-10-31): -39.0%Derived (calculated)
    • Operating income (YoY) (2025-10-31 vs 2024-10-31): -1.3%Derived (calculated)
    • Operating cash flow (YoY) (2025-10-31 vs 2024-10-31): 50.5%Derived (calculated)
    • Net margin (FY 2025-10-31): -106.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-10-31 vs 2024-10-31): -16.2%Derived (calculated)
    • EPS (basic) (YoY) (2025-10-31 vs 2024-10-31): -16.2%Derived (calculated)
    • Revenue (YoY) (2025-10-31 vs 2024-10-31): 12.5%Derived (calculated)
    • Operating income (annual): USD -5.39MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage